T-cell/histiocyte-rich large B-cell lymphoma: A distinct clinicopathologic entity

Journal of Clinical Oncology

Volumn 20, Issue 5, 2002, Pages 1269-1277

  Achten, Ruth ^a   Verhoef, G ^a   Vanuytsel, L ^a   De Wolf Peeters, C ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; PROTEIN P53; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER MODEL; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CELL SUBPOPULATION; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; GENE OVEREXPRESSION; GENETIC HETEROGENEITY; GERMINAL CENTER; HISTIOCYTE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; STATISTICAL MODEL; STROMA; T LYMPHOCYTE;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HISTIOCYTES; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; T-LYMPHOCYTES;

EID: 0036498922     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.5.1269     Document Type: Article

References (41)

1. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
2. Lymphoma classification: From controversy to consensus - The R.E.A.L. and WHO classification of lymphoid neoplasms
3. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
4. Diffuse large-cell lymphoma
5. Can we improve upon the international index?
6. A predictive model for aggressive non-Hodgkin's lymphoma: The international non-Hodgkin's lymphoma prognostic factors project
7. Pathologic prognostic factors in diffuse aggressive non-Hodgkin's lymphoma
8. Prognostic indicators in diffuse, aggressive non-Hodgkin's lymphomas: Regulators of growth fraction and programmed cell death
9. Society for Hematopathology Program: Proposed World Health Organization classification of neoplastic diseases of hematopoietic and lymphoid tissues
10. Histiocyte-rich B-cell lymphoma: A distinct clinicopathologic entity possibly related to lymphocyte predominant Hodgkin's disease, paragranuloma subtype
11. T-cell-rich B-cell lymphoma: What is new? What is cool?
12. T-cell rich B-cell lymphoma: A morphological variant of a variety of non-Hodgkin's lymphomas or a clinicopathological entity?
13. T cell/histiocyte rich large B cell lymphoma: A distinct diffuse large B cell lymphoma subtype showing characteristic morphologic and immunophenotypic features
14. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group
15. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma: The non-Hodgkin's lymphoma classification project
16. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes - Non-Hodgkin's lymphoma classification project
17. Clinical and prognostic significance of bone marrow involvement in patients with diffuse aggressive B-cell lymphoma
18. T-cell-rich B-cell lymphoma: A clinicopathologic study of eight cases
19. T-cell-rich B-cell lymphomas: Diagnosis and response to therapy of 44 patients
20. T-cell-rich large B-cell lymphoma: A study of 30 cases, supporting its histologic heterogeneity and lack of clinical distinctiveness
21. Large B-cell lymphomas with a high content of reactive T cells
22. T-cell-rich B-cell lymphoma
23. Bone marrow involvement in T-cell-rich B-cell lymphoma
24. T-cell-rich B large-cell lymphoma simulating lymphocyte-rich Hodgkin's disease
25. Morphological variability of tumour cells in T-cell-rich B-cell lymphoma: A histopathological study of 14 cases
26. T-cell-rich B-cell lymphoma presenting as liver disease
27. Large B-cell lymphoma rich in T-cells and simulating Hodgkin's disease
28. Prognostic significance of bcl-2 protein expression and bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma
29. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma: Groupe d'Etude des Lymphomes de l'Adulte (GELA)
30. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: A British national lymphoma investigation study
31. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: A population-based study
32. Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins
33. The prognostic value of Ki67 immunostaining in non-Hodgkin's lymphoma
34. Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma
35. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: A prospective Southwest Oncology Group trial
36. MIB-1 and S-phase cell fraction predict survival in non-Hodgkin's lymphomas
37. Prognostic implications of ploidy and proliferative activity in the diffuse, aggressive non-Hodgkin's lymphomas
38. CD1O and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas
39. Monoclonal antibodies PG-B6a and PG-B6p recognize, respectively, a highly conserved and a formol-resistant epitope on the human BCL-6 protein amino-terminal region
40. BCL-6 expression in reactive lymphoid tissue and in B-cell non-Hodgkin's lymphomas
41. Gene expression in diagnosis